Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

Andrew M. Intlekofer,  Alan H. Shih,  Bo Wang,  Abbas Nazir,  Ariën S. Rustenburg,  Steven K. Albanese, Minal Patel, Christopher Famulare, Fabian M. Correa, Naofumi Takemoto, Vidushi Durani, Hui Liu, Justin Taylor, Noushin Farnoud, Elli Papaemmanuil, Justin R. Cross, Martin S. Tallman, Maria E. Arcila, Mikhail Roshal, Gregory A. Petsko, Bin Wu, Sung Choe, Zenon D. Konteatis, Scott A. Biller, John D. Chodera, Craig B. Thompson, Ross L. Levine, and Eytan M. Stein
Nature 559:125, 2018. [DOI] [PDF]

We probe the biochemical and biophysical mechanisms underlying an unusual set of clinical resistance mutations that appeared in trans in the IDH2 dimer interface in cancer patients treated with IDH2 inhibitors.

L-2-Hydroxyglutarate production arises from noncanonical enzyme function at acidic pH

Intlekofer A, Wang B, Liu H, Shah H, Carmona-Fontaine C, Rustenburg AS, Salah S, Gunner MR, Chodera JD, Cross JR, and Thompson CB.
Nature Chemical Biology 13:494, 2017. [DOI] [PDF] [GitHub]

At low pH, metabolic enzymes lactate dehydrogenase and malate dehydrogenase undergo shifts in substrate utilization that have high relevance to cancer metabolism due to surprisingly simple protonation state effects.